“World-Renowned Income Expert and Author of Get Rich with Dividends Gives Away His Top Five Dividend Stocks – FOR FREE!” That’s the headline from Marc Lichtenfeld and The Oxford Club, promoting the Ultimate Dividend Package.
The offer promises five top dividend stocks, including Lichtenfeld’s “No. 1 Dividend Stock,” an “8%” dividend idea and three “Extreme Dividend” stocks. The Oxford Club says the package is 100% free with no credit card required. We identify the five best matches below, with 82/100 confidence.
Reading between the lines
The trail runs through three unusually specific report titles: “My No. 1 Dividend Stock,” “The Safest 8% Dividend in the World” and “Top Three ‘Extreme Dividend’ Stocks.” Those labels point to one headline pick, one partnership-based income stock and a three-stock high-yield group.
The same pitch also travels under “The Ultimate Dividend Package,” “FREE Ultimate Dividend Package,” “Top Five Dividend Stocks,” “Extreme Dividend Stocks,” “Dividend Package” and “Ultimate Dividend Report #3.” Different wrapping, same bundle.
The stock behind Ultimate Dividend Package
Our best identification of the five stocks is AbbVie (ABBV), Enterprise Products Partners (EPD), Cogent Communications (CCOI), Rio Tinto (RIO) and Capital Southwest (CSWC). These are matches to the teased reports, not five independently verified endorsements.
AbbVie is the headline pick. Its biotechnology and research-based biopharmaceutical description fits the unnamed breakthrough-biotech clue, while its 2018 annual report recorded $19.9 billion in global Humira sales. That combination is far too distinctive to ignore, even though several of the promotion’s supporting figures are stale or broadened beyond what the filings actually say.
EPD fits the “safest 8%” report’s partnership and toll-collector language: Enterprise Products Partners is a limited partnership operating pipelines, storage and terminals, with common unitholders rather than shareholders. The three Extreme Dividend matches line up with Wealthy Retirement’s public report, which identifies Cogent first, Rio Tinto second and Capital Southwest as the replacement third recommendation. The evidence converges cleanly, but the bonus-report trail is still thin, so 82/100 is strong confirmation rather than certainty.
Also in this offer
The offer bundles 5 bonus reports that tease their own stocks. These get a sentence or two of copy each, so the evidence is much thinner than for the main pick and what follows is our best reading rather than a confident answer.
| Bonus report | Our best guess | Confidence |
|---|
| My No. 1 Dividend Stock | ABBV — AbbVie Inc. | 82/100 — solid |
| The Safest 8% Dividend in the World | EPD — Enterprise Products Partners L.P. | 88/100 — high |
|
What survives the paperwork
The claim-by-claim check separates the identification clues from the investment promises. A promotional number can help identify a company and still fail as a current financial fact.
The sources include The Oxford Club’s package page, company annual reports and investor materials, SEC Forms 4, Wealthy Retirement’s public Extreme Dividend report and market data. The checks distinguish claims supported by those sources from claims that are stale, overstated or impossible to test from the public copy.
| The promotion claims | Verdict | What we found |
|---|
| The package offers five top dividend stocks for free. | Checks out | The Oxford Club landing page is titled “Top Five Dividend Stocks – FOR FREE!” and states that the Ultimate Dividend Package is 100% free with no credit card required. |
| The package includes Marc Lichtenfeld’s No. 1 dividend stock. | Checks out | The Oxford Club Ultimate Dividend Package page explicitly lists “My No. 1 Dividend Stock” among the included reports. |
|
Claims the record contradicts
“The three Extreme Dividend stocks are volatile small plays.” — Cogent’s market capitalization is about $516 million and Capital Southwest’s is about $1.56 billion, but Rio Tinto’s is about $165.6 billion; the three-stock set is therefore not uniformly small.
“AbbVie has raised its dividend for nearly 50 years.” — AbbVie’s own 2025 dividend release says its standalone dividend-growth record began in 2013; the more-than-50-year record belongs to former parent Abbott Laboratories.
“Enterprise Products Partners insiders bought more than $11 million of units with their own money.” — SEC Forms 4 for Enterprise executives A. James Teague, R. Daniel Boss and Graham W. Bacon show phantom-unit awards, vesting and tax-withholding transactions, not more than $11 million of open-market purchases with personal cash.
“Cogent Communications has an unusually high, repeatedly increased dividend.” — Cogent’s investor presentation documented 52 consecutive quarterly increases through 2025, but its 2025 Form 10-K and dividend history show a cut from $1.015 to $0.02 per share in the fourth quarter of 2025.
Where the pitch outran the record
“AbbVie’s pipeline is expected to generate $35 billion in sales.” — An AbbVie investor presentation projected more than $35 billion of non-Humira sales in 2025, but that broader marketed-product estimate is not the same as a $35 billion pipeline-sales forecast.
“AbbVie paid shareholders $6 billion in dividends over the past year.” — AbbVie’s 2024 annual report shows $11.025 billion of dividends paid, so the promoted $6 billion figure is dated or otherwise not a current total-company dividend figure.
“AbbVie has about $14 billion in free cash flow.” — AbbVie’s 2025 Form 10-K reports $19.030 billion of operating cash flow and $1.214 billion of capital expenditures, implying approximately $17.8 billion of free cash flow rather than $14 billion.
“Without Enterprise Products Partners, essential products cannot reach Americans across the country.” — Enterprise operates important North American midstream infrastructure, but its Form 10-K does not establish the promotion’s categorical claim that essential products cannot reach Americans without the company.
“Enterprise Products Partners has $36 billion in annual revenue.” — Enterprise reported $56.219 billion of revenue in 2024 and about $58.5 billion in the latest valuation figures; $36.534 billion was the company’s 2018 revenue, making the promoted figure stale when presented as current.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Other pitches from the same analyst
This is the third Marc Lichtenfeld promotion we’ve identified. The first two were “Trump Nuclear Mega-BOOM,” which pointed to enCore Energy and is up 8.7% since we named it, and “29% Account,” which pointed to Texas Pacific Land and is down 10.8% since we named it.
That’s two prior observations, not a performance record. It is still useful ledger work: this package belongs to a recognizable stream of Lichtenfeld promotions rather than arriving in isolation.
Setting the pitch aside: is it any good?
The pitch’s central claim is simple: investors can get five high, safe and durable dividend stocks at bargain prices. The durable-income link has real support, but the bargain and safety links are doing far more work than the evidence can carry.
Enterprise Products Partners gives the argument its cleanest support. Its 2025 Form 10-K and February 2026 earnings release support 27 consecutive years of distribution growth, and investor materials show cash flow covering distributions comfortably. But the “8%” label doesn’t survive the market check: the annualized distribution implied a yield near 5.8% on August 10, 2026. A toll collector can be real without being an 8% bargain.
The AbbVie case is stronger as an identification than as a clean sales pitch. Humira’s $19.9 billion figure is historical, the more-than-$35 billion estimate referred to broader marketed products rather than just the pipeline, and the nearly 50-year dividend streak belongs to former parent Abbott Laboratories, not standalone AbbVie. Cogent’s dividend history has an even sharper break: after 52 consecutive quarterly increases, its per-share dividend fell from $1.015 to $0.02 in the fourth quarter of 2025. Rio Tinto also punctures the “volatile small plays” framing with a market capitalization of about $165.6 billion.
As a basket, these aren’t five interchangeable safe-income machines. EPD and CSWC carry the strongest high-income thesis, while AbbVie has a credible cash-generation and biopharma case on its own merits. Rio Tinto brings cyclical mining exposure, and Cogent’s dividend cut demands attention rather than a footnote. The package is worth investigating; the claim that every pick is simultaneously cheap, safe and extreme is where it loses its footing.
How confident are we? 82 out of 100. We identified AbbVie Inc. (ABBV) from the promotion's own clues and checked 34 of its claims against filings, earnings calls, ownership records, market data and public reporting. This is our analysis, not the publisher's disclosure — we have no relationship with them.
